Research of rational use of apatinib mesylate / 中国药学杂志

ABSTRACT

OBJECTIVE: To investigate and analyze the rational use of apatinib in cancer hospital. METHODS: Retrospective study was applied. Through reviewing medical records, the patient' s basic information, drug therapy information and adverse drug effects were collected and analyzed. RESULTS: Apatinib is mainly used in patients with advanced metastatic gastric or esophagogastric junction cancer who have failed at least two chemotherapeutic regimens. The clinical common dose of apatinib was 0.25 or 0.5 g, less than the dose of 0.85 g recommended in drug instruction. CONCLUSION: Apatinib is a new choice for gastric or esophagogastric junction cancer. It has demonstrated tolerable adverse effects in these patients. However, at present, more attentions should be paid to possible effect of drug dose on clinical outcome.